comprehensive -WSS

comprehensive

author：explore 2025-09-30 01:14:59 - browse：5724

Fran van Delft for Galapagos

Seeking to differentiate itself from other makers of CAR-T cancer therapies, Galapagos NV on Wednesday announced it had struck a deal with Blood Centers of America to open up dozens of manufacturing sites for its cell-based medicines around the U.S.

Galapagos said it will rely on the partnership, the financial terms of which were not disclosed, as it moves its CAR-Ts for different cancers into pivotal studies and could also help launch those medicines should they win approval. The Belgian company framed the collaboration as one that could help overcome the limitations that have held back access to existing CAR-T therapies from other companies.

CAR-Ts have proven to be potent treatments for certain cancers, but they are complicated medicines to make. Immune cells have to be removed from a patient, shipped to specialty sites, where they’re engineered with cancer-killing abilities, and then returned to the hospital for infusion back into patients. The process, which can take weeks if not months, has put a crunch on the number of patients companies and hospitals are able to treat.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Campaign finance charge dropped from case against Sam Bankman

WSS

'Weather

5 wounded, 2 critically, in Michigan shopping center shooting

FDA struggles to regulate food additives, sometimes for decades

Hospital price transparency does save money, advocate argues

American TikTok star stuck in Dubai for months following rental car altercation

'Weather

entertainment

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

As demand for Covid shots wanes, Moderna seeks its next success

STAT Summit: GSK CEO on pharma giant's new direction

BioMarin wins approval for gene therapy to treat hemophilia A

First Opinion Podcast: Long Covid needs a new approach

Continuity nursing helped my family in our darkest PICU moments

Studies point to risks of excluding people with obesity from drug trials

Medical records are filled with copy

HHS leader on health, climate change and biopharma emissions

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

HHS leader on health, climate change and biopharma emissions

hotspot

9 mass shootings over the weekend rock US cities, leaving 5 dead, 56 injured

Fla. should 'correct' controversial slavery curriculum: Republican Rep. Byron Donalds

STAT Summit: Biotech founders on deal

Adidas to release second batch of Yeezy sneakers after breakup with Ye

Doctors increasingly discourage vaping amid mounting health concerns

The EU Joint Clinical Assessment needs to live up to its promise

Wikipedia

Wikipedia

focus

knowledge